IxC 162

Drug Profile

IxC 162

Latest Information Update: 03 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ixion Biotechnology
  • Class Enzymes
  • Mechanism of Action Oxalate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Crohn's disease; Cystic fibrosis; Inflammatory bowel diseases; Kidney disorders

Most Recent Events

  • 03 Dec 2003 No development reported - Preclinical for Crohn's disease in USA (unspecified route)
  • 03 Dec 2003 No development reported - Preclinical for Cystic fibrosis in USA (unspecified route)
  • 03 Dec 2003 No development reported - Preclinical for Inflammatory bowel disease in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top